The Drug Controller General of India (DCGI) on January 3 granted permission for restricted emergency use of the AstraZeneca-Oxford University and Bharat Biotech Covid-19 vaccines. The approval was based on the recommendations of the Subject Expert Committee (SEC), which reviewed the data on safety and immunogenicity of the two vaccines. However, post the announcement it is India’s indigenous vaccine which has found itself in the middle of a controversy. Here’s why.
first published: Jan 4, 2021 06:46 pm
A collection of the most-viewed Moneycontrol videos.
